Akero Therapeutics Inc AKRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
-
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
-
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
-
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
-
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 58
- Website
- https://www.akerotx.com
Comparables
Valuation
|
Metric
|
AKRO
|
EWTX
|
TVTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.45 | 4.79 | 70.72 |
Price/Sales | — | — | 6.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
AKRO
EWTX
TVTX
Financial Strength
|
Metric
|
AKRO
|
EWTX
|
TVTX
|
|---|---|---|---|
Quick Ratio | 24.39 | 29.79 | 2.89 |
Current Ratio | 24.89 | 30.24 | 3.04 |
Interest Coverage | −60.64 | — | −35.20 |
Quick Ratio
AKRO
EWTX
TVTX
Profitability
|
Metric
|
AKRO
|
EWTX
|
TVTX
|
|---|---|---|---|
Return on Assets (Normalized) | −24.18% | −23.23% | −9.03% |
Return on Equity (Normalized) | −26.16% | −24.43% | −47.00% |
Return on Invested Capital (Normalized) | −30.54% | −29.19% | −13.68% |
Return on Assets
AKRO
EWTX
TVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Msppcpdt | Yjjc | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mbbmxnjgd | Zvpgsdm | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vvcwgvmwd | Nrymdj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xbwvgwm | Ysqbjh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Bvtjgvh | Yfntj | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Snkqjqsg | Qqd | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xqfkxwfv | Znrh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Kcdbnpycd | Tdw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rnsykxvlz | Pbmbvjm | $13.4 Bil | |||
| Incyte Corp
INCY
| Mjzlfzcj | Mtqmv | $12.7 Bil |
United States